Guidelines in the management of diabetic nerve pain clinical utility of pregabalin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Diabetic peripheral neuropathy is a common complication of diabetes. It presents as a variety of syndromes for which there is no universally accepted unique classification. Sensorimotor polyneuropathy is the most common type, affecting about 30% of diabetic patients in hospital care and 25% of those in the community. Pain is the reason for 40% of patient visits in a primary care setting, and about 20% of these have had pain for greater than 6 months. Chronic pain may be nociceptive, which occurs as a result of disease or damage to tissue with no abnormality in the nervous system. In contrast, neuropathic pain is defined as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system." Persistent neuropathic pain interferes significantly with quality of life, impairing sleep and recreation; it also significantly impacts emotional well-being, and is associated with depression, anxiety, and noncompliance with treatment. Painful diabetic peripheral neuropathy is a difficult-to-manage clinical problem, and patients with this condition are more apt to seek medical attention than those with other types of diabetic neuropathy. Early recognition of psychological problems is critical to the management of pain, and physicians need to go beyond the management of pain per se if they are to achieve success. This evidence-based review of the assessment of the patient with pain in diabetes addresses the state-of-the-art management of pain, recognizing all the conditions that produce pain in diabetes and the evidence in support of a variety of treatments currently available. A search of the full Medline database for the last 10 years was conducted in August 2012 using the terms painful diabetic peripheral neuropathy, painful diabetic peripheral polyneuropathy, painful diabetic neuropathy and pain in diabetes. In addition, recent reviews addressing this issue were adopted as necessary. In particular, reports from the American Academy of Neurology and the Toronto Consensus Panel on Diabetic Neuropathy were included. Unfortunately, the results of evidence-based studies do not necessarily take into account the presence of comorbidities, the cost of treatment, or the role of third-party payers in decision-making. Thus, this review attempts to give a more balanced view of the management of pain in the diabetic patient with neuropathy and in particular the role of pregabalin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690 · cited 1×
“Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013:6 metabolic and microvascular alterations as a result of chronic hyperglycemia exposure (diabetes) and cardiovascular risk covariates.(3) Its onset is generally insidious, and without treatment its course is chronic and progressive.”
Self-citationFreynhagen, R., Baron, R., Gockel, U., & Tölle, T. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132488 · Cited by 2,280
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562 · cited 1×
“41 53 Others assess pain quality and intensity (assessment questionnaires such as the short-form McGill Pain Questionnaire, the BPI, and the Neuropathic Pain Symptom Inventory) 48,54,55”
Development and validation of the Neuropathic Pain Symptom Inventory
Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., Rostaing, S., Lanteri-Minet, M., Collin, E., Grisart, J., et al. (2004) · Pain · doi:10.1016/j.pain.2003.12.024 · Cited by 1,329
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Abbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Dworkin, R. H., Turk, D. C., Revicki, D. A., Harding, G., Coyne, K. S., Peirce-Sandner, S., Bhagwat, D., Everton, D., Burke, L. B., Cowan, P., et al. (2009) · Pain · doi:10.1016/j.pain.2009.02.007 · Cited by 761 · cited 1×
“41 53 Others assess pain quality and intensity (assessment questionnaires such as the short-form McGill Pain Questionnaire, the BPI, and the Neuropathic Pain Symptom Inventory) 48,54,55”
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K.-S., & Stacey, B. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.04.009 · Cited by 525 · cited 1×
“As a corollary, Gore et al 17 showed that with increasing pain severity, there was a linear increase in Hospital Anxiety and Depression Scale pain and depression scores.”
O'Connor (2009) · doi:10.2165/00019053-200927020-00002 · Cited by 438
Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S. H., Perkins, B. A., Baconja, M., Vinik, A. I., Boulton, A. J. M., & Neuropathy, O. B. O. T. T. E. P. O. D. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1225 · Cited by 410 · cited 7×
“5% of subjects discontinued, most often due to adverse events.(72,128) Recently, Boyd et al have shown that relief of pain with topiramate treatment associated with improvement in subjective and objective measures of nerve function, intraepidermal nerve-fiber regeneration (Class Ib, recommendation A [see Supplementary…”
InfluentialSelf-citationZiegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00555.x · Cited by 249 · cited 1×
“2% in those with normal glucose tolerance.(31) Among survivors of myocardial infarction (MI) from the Augsburg MI Registry, the prevalence of neuropathic pain was 21% in patients with diabetes, 14.”
Small fiber neuropathy is associated with the metabolic syndrome
Pittenger, G. L., Mehrabyan, A., Simmons, K., Amandarice, Dublin, C., Barlow, P., & Vinik, A. I. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.113 · Cited by 116
Self-citationDoes Treatment With Duloxetine for Neuropathic Pain Impact Glycemic Control?
Hardy, T., Sachson, R., Shen, S., Armbruster, M., & Boulton, A. J. M. (2007) · Diabetes Care · doi:10.2337/dc06-0947 · Cited by 79
Cited by
Vinik, A. I., Nevoret, M.-L., Casellini, C., & Parson, H. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.001 · Cited by 366
Self-citationBouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., Freynhagen, R., Tesfaye, S., Lledó, A., Choy, E., et al. (2014) · Pain · doi:10.1016/j.pain.2014.08.020 · Cited by 132
“Evidence suggests that in painful diabetic neuropathy, only a few drugs achieve greater than 30% reduction in pain in more than 50% of patients [21,22,26,28].”
BackgroundDiabetic Sensory and Motor Neuropathy
Vinik, A. I. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1503948 · Cited by 113
Self-citation
Metadata
- Authors
- Vinik, A., & Casellini
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-02
- Volume
- 6
- Pages
- 57
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W1995301420
- Cited by
- 63
- References
- 17
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.